HCV / Hepatitis

Study examines the scarcity of data on the incidence of HBV-related hepatocellular carcinoma in West Africa.

On the day of a FDA PDUFA for a hepatitis B vaccine, it serves as reminder of great progress, but there remains a need to proliferate education especially around the liver.

Analysis reveals rising hospitalization rates among pregnant women with hepatitis C virus (HCV) and age as a critical factor influencing maternal and fetal health outcomes.

The modified difference-in-differences analysis found notable increases in DAA use after state Medicaid programs relaxed certain coverage restrictions.

This week, April FDA roundup, ESCMID conference coverage, enhancing C difficile treatment, and more from Contagion.

This study monitored viral load in asymptomatic blood donors, unveiling insights into the progression of HEV infections, vital for public health strategies.

Public health alert over ground beef, FDA approves antibiotics for female adults with uncomplicated UTI, The NYC Department of Health and Mental Hygiene reports a record amount of Leptospirosis cases, and more this week from Contagion.

Study from the Journal of Hepatology aims to characterize immune responses associated with rapid natural clearance of HCV reinfection.

The vaccine’s developer, YS Biopharma, will begin its phase 1 clinical trial in the Philippines this summer.

Study highlighting the first documented case of C auris moving from adult to pediatric unit in Maryland, COVID-19 physical health problems lingering 1 year after their hospital stay, 5-in-1 meningococcal vaccine given FDA PDUFA, and more this week from Contagion.

Please join advocates for prevention to celebrate the miracles the liver performs in maintaining the bodies’ systems, and ways to increase education to the public about the organ.

An analysis of NHANES data looked at HCV infection and risk of prostate cancer, and found contrary evidence from previous research.

Current progress of WHO's strategies to enhance global health outcomes through improved diagnosis and treatment of viral hepatitis.

Study evaluates the outcomes of orthotopic liver transplantation of HIV-HBV coinfected patients.

Study shows GBP1 assists HCV in the replication and spread against antiviral expectations.

Alcohol Awareness Month highlights the need for action amidst the alcohol crisis in the US.

Clinicians discuss screening and treatment approaches for the disease.

Insights from a CDC study on challenges and research direction in pediatric hepatitis.

Bulevirtide's key role in blocking hepatitis virus entry.

Insights on Sofosbuvir levels in pregnant women.

The evolution of treatment for hepatitis C virus during the past 15 years has been astounding, and we now are able to talk about how HCV could be eliminated.

Here is a review of an opportunistic treatment approach to HCV infection in this patient population in a European study and some of the potential challenges in applying it in the United States.

Wireless test kit transforms screening efforts towards combating the virus.

New analysis indicates that children treated at 3 years of age for perinatally acquired HCV will live longer, with less liver morbidity and lower health care costs than if treated at 6 years of age.

A vaccine targeting chronic HBV has entered its first human trial; Saskia Popescu, PhD, on the importance of pandemic preparedness and global health security; a successful phase 2 trial for a C diff treatment leads to the next phase; and more stories this week from Contagion.

This year at the Conference on Retroviruses and Opportunistic Infections (CROI), Lenacapavir shows virological suppression, Remdesivir reduces long covid risks, Bulevirtide benefits chronic HBV, HIV treatment enhances outcomes, vaginal ring or oral pre-exposure prophylaxis safe for HIV prevention throughout pregnancy.

Vaccine designed to confront chronic HBV entering its first human clinical trial.

Insights from CROI on the HepB-CpG vaccine trial.

Insights from phase 3 study evaluating bulevirtide efficacy in coinfections.

Study presented at CROI 2024 reveals chronic hepatitis B virus (HBV) infection heightens COVID-19 severity as vaccination reduces mortality and ICU demands in co-infected individuals.